Ad hoc announcement pursuant to Art. 53 LR Idorsia receives a positive opinion from the Committee for Medicinal Products for Human Use for QUVIVIQ (daridorexant) for the treatment of adult patients
Idorsia Ltd (SIX: IDIA) today announced the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion for the use of QUVIVIQ™ (daridorexant) as the first dual orexin receptor antagonist in the European Union (EU) for the t.
GNW: QUVIVIQ (daridorexant) recommended for approval in Europe as a new | Newsticker fuw.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fuw.ch Daily Mail and Mail on Sunday newspapers.